Title:
SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2021/083167
Kind Code:
A1
Abstract:
A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs.
Inventors:
ZHOU FUSHENG (CN)
JIANG TAO (CN)
LIN CHONGLAN (CN)
CAI LIJIAN (CN)
HE WAN (CN)
LAN JIONG (CN)
JIANG TAO (CN)
LIN CHONGLAN (CN)
CAI LIJIAN (CN)
HE WAN (CN)
LAN JIONG (CN)
Application Number:
PCT/CN2020/124226
Publication Date:
May 06, 2021
Filing Date:
October 28, 2020
Export Citation:
Assignee:
GENFLEET THERAPEUTICS SHANGHAI INC (CN)
ZHEJIANG GENFLEET THERAPEUTICS CO LTD (CN)
ZHEJIANG GENFLEET THERAPEUTICS CO LTD (CN)
International Classes:
C07D403/04; A61K31/495; A61P35/00; C07D471/00
Domestic Patent References:
| WO2019213516A1 | 2019-11-07 | |||
| WO2018217651A1 | 2018-11-29 | |||
| WO2019051291A1 | 2019-03-14 |
Foreign References:
| CN106488910A | 2017-03-08 |
Other References:
See also references of EP 4053118A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: